The American Society of Clinical Oncology (ASCO) annual meeting will be closely watched by analysts and investors alike. There is no doubt that favorable data presented at the event will advance a company's stock valuation significantly. Equally, candidate cancer therapies that do not live up to expectations will see their developers face the ire of investors.
Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) leapt 36% higher to $42.12 on Thursday after limited data from a small number of relapsed/refractory (r/r) non-Hodgkin lymphoma patients showed a combination of the company's anti-CD19 allogeneic CAR T candidate, ALLO-501, and an anti-CD52 monoclonal antibody, ALLO-647, met with an overall response rate of 78%.
New data show Johnson & Johnson’s Erleada (apalutamide) and Xtandi (enzalutamide) from Pfizer Inc. and Astellas Pharma Inc. both prolonged overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
New and updated preclinical and clinical data to be presented by biopharma firms at the American Society of Clinical Oncology’s annual meeting May 29-31, including: Allogene, Arvinas, Astrazeneca, Exelixis, Eli Lilly, Galera, Heat, Helsinn, Immunogen, Innate, Innovent, Inovio, Janssen, Kyowa, Legend, Marker, MEI, Merck, Targovax, Tarveda, Tiziana, Vaximm, Xencor.
RSS
